<DOC>
	<DOCNO>NCT00443131</DOCNO>
	<brief_summary>In study , two experimental malaria vaccine ( adjuvant ) test evaluate characterise vaccine exactly work immune system compare control ( without adjuvant ) . The Protocol Posting update order comply FDA Amendment Act , Sep 2007 .</brief_summary>
	<brief_title>Characterisation Immune Responses 2 Experimental Malaria Vaccines</brief_title>
	<detailed_description />
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe comply requirement protocol . A male female , include , 18 45 year age time first vaccination . Written inform consent obtain subject . Free obvious health problem establish medical history clinical examination enter study . Have clinically normal laboratory value creatinine , alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) , complete blood count ( CBC ) differential screening . Be seronegative human immunodeficiency virus1 2 ( HIV 1/2 ) antibody , HBsAg hepatitis C virus ( HCV ) antibody . Have anti HBs titre â‰¥ 10mIU/ml screening . If subject female , must nonchildbearing potential childbearing potential , must practice adequate contraception 30 day prior vaccination , negative pregnancy test continue precaution 2 month completion vaccination series . Use investigational nonregistered product ( drug vaccine ) study vaccine ( ) within 30 day precede first dose study vaccine , plan use study period . Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug within 6 month prior first vaccine dose . Planned administration/ administration vaccine foreseen study protocol within 30 day first dose vaccine . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational product ( pharmaceutical product device ) . Any history clinical malaria . Known exposure malaria parasite within previous 12 month . Planned travel malaria endemic region study period . History allergic reaction anaphylaxis previous immunization . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination . Personal history autoimmune disease subject describe firstdegree relative clearly document autoimmune disease . History allergic disease reaction likely exacerbate component vaccine ( ) . Major congenital defect serious chronic illness ( e ) . Acute disease time enrolment . History neurologic disorder seizure . Acute chronic , clinically significant pulmonary , cardiovascular , hepatic renal functional abnormality , determine physical examination laboratory screen test . Hepatomegaly , right upper quadrant abdominal pain tenderness . Administration immunoglobulins and/or blood product within three month precede first dose study vaccine plan administration study period . History previous exposure experimental product contain component vaccine use study . Pregnant lactate female . History chronic alcohol consumption and/or drug abuse . Female plan become pregnant planning discontinue contraceptive precaution .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>Adjuvant</keyword>
	<keyword>Malaria</keyword>
	<keyword>Safety</keyword>
	<keyword>Immunogenicity</keyword>
</DOC>